RU2013114246A - Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении - Google Patents
Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении Download PDFInfo
- Publication number
- RU2013114246A RU2013114246A RU2013114246/15A RU2013114246A RU2013114246A RU 2013114246 A RU2013114246 A RU 2013114246A RU 2013114246/15 A RU2013114246/15 A RU 2013114246/15A RU 2013114246 A RU2013114246 A RU 2013114246A RU 2013114246 A RU2013114246 A RU 2013114246A
- Authority
- RU
- Russia
- Prior art keywords
- combination
- drug
- thrombocytopenia
- group
- use according
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 16
- 206010043554 thrombocytopenia Diseases 0.000 title claims abstract 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 claims abstract 12
- 239000003112 inhibitor Substances 0.000 claims abstract 6
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract 4
- 229960001069 eltrombopag Drugs 0.000 claims abstract 4
- XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 claims abstract 4
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims abstract 4
- 229960004262 romiplostim Drugs 0.000 claims abstract 4
- 108010017584 romiplostim Proteins 0.000 claims abstract 4
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims abstract 4
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims abstract 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims abstract 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims abstract 2
- 230000000340 anti-metabolite Effects 0.000 claims abstract 2
- 229940100197 antimetabolite Drugs 0.000 claims abstract 2
- 239000002256 antimetabolite Substances 0.000 claims abstract 2
- 229960002756 azacitidine Drugs 0.000 claims abstract 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims abstract 2
- 229960001467 bortezomib Drugs 0.000 claims abstract 2
- 229960003603 decitabine Drugs 0.000 claims abstract 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract 2
- 229960003957 dexamethasone Drugs 0.000 claims abstract 2
- 229960005184 panobinostat Drugs 0.000 claims abstract 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims abstract 2
- 229960003452 romidepsin Drugs 0.000 claims abstract 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims abstract 2
- 108010091666 romidepsin Proteins 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960000237 vorinostat Drugs 0.000 claims abstract 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Применение комбинации (а) N-гидрокси-3-[4-[[[2-(2-метил-1H-индол-3-ил)этил]амино]метил]фенил]-2Е-2-пропенамида или его фармацевтически приемлемой соли в комбинации с (b) лекарственным препаратом против тромбоцитопении для получения лекарственного средства, предназначенного для лечения множественной миеломы.2. Применение по п.1, где лекарственным средством против тромбоцитопении является ТПО-миметик.3. Применение по п.2, где лекарственным средством против тромбоцитопении является элтромбопаг, ромиплостим или их сочетание.4. Применение по п.3, где комбинация дополнительно включает дополнительное лекарственное средство, эффективное для лечения множественной миеломы.5. Применение по п.4, где лекарственным средством является протеосомный ингибитор.6. Применение по п.5, где протеосомным ингибитором является бортезомиб.7. Применение по п.6, где комбинация дополнительно включает дексаметазон.8. Применение комбинации, содержащей(a) HDACi ингибитор, выбранный из группы, состоящей из панобиностата, ромидепсина, вориностата и их сочетаний;(b) лекарственное средство против ТЦП, выбранное из группы, состоящей из элтромбопага, ромиплостима или их сочетания; и необязательно(c) анти-метаболит, выбранный из группы, состоящей из 5-азацитидина, децитабина или их сочетания;для получения лекарственного средства, предназначенного для лечения МДС и/или ОМЛ.
Claims (8)
1. Применение комбинации (а) N-гидрокси-3-[4-[[[2-(2-метил-1H-индол-3-ил)этил]амино]метил]фенил]-2Е-2-пропенамида или его фармацевтически приемлемой соли в комбинации с (b) лекарственным препаратом против тромбоцитопении для получения лекарственного средства, предназначенного для лечения множественной миеломы.
2. Применение по п.1, где лекарственным средством против тромбоцитопении является ТПО-миметик.
3. Применение по п.2, где лекарственным средством против тромбоцитопении является элтромбопаг, ромиплостим или их сочетание.
4. Применение по п.3, где комбинация дополнительно включает дополнительное лекарственное средство, эффективное для лечения множественной миеломы.
5. Применение по п.4, где лекарственным средством является протеосомный ингибитор.
6. Применение по п.5, где протеосомным ингибитором является бортезомиб.
7. Применение по п.6, где комбинация дополнительно включает дексаметазон.
8. Применение комбинации, содержащей
(a) HDACi ингибитор, выбранный из группы, состоящей из панобиностата, ромидепсина, вориностата и их сочетаний;
(b) лекарственное средство против ТЦП, выбранное из группы, состоящей из элтромбопага, ромиплостима или их сочетания; и необязательно
(c) анти-метаболит, выбранный из группы, состоящей из 5-азацитидина, децитабина или их сочетания;
для получения лекарственного средства, предназначенного для лечения МДС и/или ОМЛ.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37923810P | 2010-09-01 | 2010-09-01 | |
| US61/379,238 | 2010-09-01 | ||
| PCT/US2011/049842 WO2012030886A1 (en) | 2010-09-01 | 2011-08-31 | Combination of hdac inhibitors with thrombocytopenia drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013114246A true RU2013114246A (ru) | 2014-10-20 |
Family
ID=44645808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013114246/15A RU2013114246A (ru) | 2010-09-01 | 2011-08-31 | Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130171141A1 (ru) |
| EP (1) | EP2611436A1 (ru) |
| JP (2) | JP2013538810A (ru) |
| KR (1) | KR20130101519A (ru) |
| CN (2) | CN104399081A (ru) |
| AU (1) | AU2011296047A1 (ru) |
| BR (1) | BR112013004714A2 (ru) |
| CA (1) | CA2808908A1 (ru) |
| MX (1) | MX2013002503A (ru) |
| RU (1) | RU2013114246A (ru) |
| WO (1) | WO2012030886A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6551963B2 (ja) * | 2014-05-14 | 2019-07-31 | 国立大学法人京都大学 | 巨核球前駆細胞の製造方法 |
| US10702517B2 (en) * | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| EP3534965A4 (en) * | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | IMPROVEMENTS TO CD47 BLOCKING THERAPY BY HDAC INHIBITORS |
| CN115820865B (zh) * | 2023-01-31 | 2024-08-27 | 南京中医药大学 | Pnpo基因在制备多发性骨髓瘤标志物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| ES2545076T3 (es) * | 2005-08-03 | 2015-09-08 | Novartis Ag | Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma |
| AU2006311808A1 (en) * | 2005-11-04 | 2007-05-18 | Merck Sharp & Dohme Corp. | Methods of using SAHA and bortezomib for treating cancer |
| MY148893A (en) * | 2006-12-04 | 2013-06-14 | Novartis Ag | Combination of an hdac inhibitor and an antimetabolite |
| CN101626758A (zh) * | 2007-02-15 | 2010-01-13 | 诺瓦提斯公司 | 用于治疗癌症的lbh589和其他治疗剂的组合 |
| UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| WO2010009285A1 (en) * | 2008-07-18 | 2010-01-21 | Novartis Ag | Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome |
| CA2732294A1 (en) * | 2008-07-30 | 2010-02-04 | Gloucester Pharmaceuticals, Inc. | Accelerated therapy |
-
2011
- 2011-08-31 AU AU2011296047A patent/AU2011296047A1/en not_active Abandoned
- 2011-08-31 EP EP11755492.3A patent/EP2611436A1/en not_active Withdrawn
- 2011-08-31 CA CA2808908A patent/CA2808908A1/en not_active Abandoned
- 2011-08-31 BR BR112013004714A patent/BR112013004714A2/pt not_active IP Right Cessation
- 2011-08-31 MX MX2013002503A patent/MX2013002503A/es not_active Application Discontinuation
- 2011-08-31 KR KR1020137008049A patent/KR20130101519A/ko not_active Withdrawn
- 2011-08-31 JP JP2013527242A patent/JP2013538810A/ja active Pending
- 2011-08-31 RU RU2013114246/15A patent/RU2013114246A/ru not_active Application Discontinuation
- 2011-08-31 CN CN201410719941.0A patent/CN104399081A/zh active Pending
- 2011-08-31 WO PCT/US2011/049842 patent/WO2012030886A1/en not_active Ceased
- 2011-08-31 US US13/819,735 patent/US20130171141A1/en not_active Abandoned
- 2011-08-31 CN CN2011800424183A patent/CN103079551A/zh active Pending
-
2015
- 2015-11-30 US US14/954,115 patent/US20160199350A1/en not_active Abandoned
-
2016
- 2016-01-06 JP JP2016001183A patent/JP2016128437A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013538810A (ja) | 2013-10-17 |
| EP2611436A1 (en) | 2013-07-10 |
| BR112013004714A2 (pt) | 2016-05-17 |
| WO2012030886A1 (en) | 2012-03-08 |
| AU2011296047A1 (en) | 2013-03-21 |
| US20160199350A1 (en) | 2016-07-14 |
| CA2808908A1 (en) | 2012-03-08 |
| US20130171141A1 (en) | 2013-07-04 |
| JP2016128437A (ja) | 2016-07-14 |
| CN103079551A (zh) | 2013-05-01 |
| MX2013002503A (es) | 2013-04-29 |
| CN104399081A (zh) | 2015-03-11 |
| KR20130101519A (ko) | 2013-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
| TN2009000344A1 (en) | Combinations of therapeutic agents for treating cancer | |
| CY1109363T1 (el) | Υδροξαμικες ενωσεις ως θεραπευτικοι παραγοντες | |
| AR045318A1 (es) | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa | |
| EA201490016A1 (ru) | Комбинация панобиностата и руксолитинаба при лечении рака, такого как миелопролиферативное новообразование | |
| EA200800798A1 (ru) | Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха | |
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| JP2013515002A5 (ru) | ||
| MX2014000130A (es) | Procedimientos y composiciones para la inhibicion de resorcion osea. | |
| NO20061253L (no) | Acetylenderivater som inhibitorer av histon deacetylase | |
| RU2018130831A (ru) | Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии | |
| PE20080852A1 (es) | Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida | |
| RU2013114246A (ru) | Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении | |
| EA201270266A1 (ru) | Гетероциклические соединения | |
| RU2008107871A (ru) | Применение ингибиторов hdac для лечения миеломы | |
| Zhang et al. | Noval advance of histone modification in inflammatory skin diseases and related treatment methods | |
| NO20085028L (no) | Substituerte karboksamider | |
| EA201170784A1 (ru) | Гранулы тамсулозина для фиксированной комбинации | |
| RU2016119493A (ru) | Пролекарства антагониста NMDA | |
| CY1111430T1 (el) | Χρηση της αγομελατινης για τη ληψη φαρμακων που προοριζονται για τη θεραπεια του συνδρομου smith magenis | |
| RU2008129635A (ru) | Ингибиторы ссr9 активности | |
| RU2008108911A (ru) | Комбинация органических соединений | |
| AR063895A1 (es) | Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de la leucomalacia periventricular | |
| DE602008001877D1 (de) | Behandlung fäkalischer inkontinenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160825 |